Isopamicin Sulfate Injection

1 Pharmacology This product belongs to aminoglycoside antibiotics. The antibacterial spectrum is similar to gentamicin. It has strong antibacterial effects on Escherichia coli, Citrobacter, Klebsiella, Enterobacter, Serratia, Proteus, Pseudomonas aeruginosa, etc. This product is more stable than other similar drugs to aminoglycoside antibiotic modification enzymes, so there are fewer resistant bacteria and less cross-resistance with other aminoglycoside antibiotics. The mechanism of action of this product is to bind to the 30S subunit of bacterial ribosomes and inhibit the synthesis of bacterial proteins. 2 Toxicology In subacute and chronic toxicity experiments, kidney damage such as degeneration of urinary tubule epithelial cells occurred, and the degree was related to the dosage. In the toxicity experiment on the auditory organ, guinea pigs were continuously injected intramuscularly with this product for 28 days. When the dose of the test group was greater than 100 mg/kg/day, the ear shell reflex of the animal disappeared, and when the dose was greater than 50 mg/kg/day, the hair cells outside the snail spiral disappeared. In the kidney toxicity experiment, rats were given intramuscular injections of 50-300 mg/kg/day of this product for 21 consecutive days, and the results showed drug-related increases in blood urea nitrogen (BUN) and serum creatinine values.

The main ingredient of this product is isopamicin sulfate

This product is a colorless, clear solution.

This product is mainly suitable for trauma or burn wound infection caused by sensitive bacteria, pneumonia, bronchitis, pyelonephritis, cystitis, peritonitis and sepsis, etc.

Intramuscular injection or intravenous drip. Adults: 400 mg per day, divided into 1 to 2 doses. Intravenous drip should be performed according to the following requirements: when administered once a day, the drip time should not be less than 1 hour; when administered twice a day, the drip time should be controlled to 30 to 60 minutes. It can be adjusted appropriately according to the patient's age, constitution and symptoms. Patients with renal insufficiency should adjust the dosage and dosing interval according to the degree of renal impairment.

1. Common symptoms include hearing loss, tinnitus or fullness in the ears (ototoxicity), hematuria, significantly reduced urination frequency or urine volume, loss of appetite, extreme thirst (nephrotoxicity), unsteady gait, dizziness (ototoxicity, affecting the vestibule), nausea or vomiting (ototoxicity, affecting the vestibule; nephrotoxicity). 2. Rare symptoms include vision loss (optic neuritis), breathing difficulties, drowsiness, extreme weakness (neuromuscular blockade), allergic reactions such as rashes, changes in blood counts, changes in liver function, digestive tract reactions, and pain and nodules at the injection site. 3. Very rare anaphylactic shock.

1. Patients who are allergic to this product or other aminoglycosides and bacitracin, or who have family members who have developed deafness due to the use of other aminoglycoside antibiotics are contraindicated. 2. Patients with renal failure are contraindicated.

1. This product can increase ototoxicity, nephrotoxicity and neuromuscular blocking effects when used in combination with other aminoglycosides or when applied topically or systemically one after the other. Hearing loss may occur, and may still progress to deafness after discontinuation of the drug; hearing damage may recover or become permanent. Neuromuscular blocking effects can lead to skeletal muscle weakness, respiratory depression or respiratory paralysis (apnea), and anticholinesterase drugs or calcium salts can help restore the blocking effect. 2. This product can aggravate neuromuscular blocking effects when used in combination with neuromuscular blocking drugs, leading to muscle weakness, respiratory depression or respiratory paralysis (apnea). When used in combination with plasma substitutes such as dextran, sodium alginate, diuretics such as ethacrynic acid, furosemide, capreomycin, cisplatin, vancomycin, etc., or when applied topically or systemically one after the other, ototoxicity and nephrotoxicity may be increased, and hearing damage may occur, and may still progress to deafness after discontinuation of the drug, and hearing damage may recover or become permanent. 3. This product can increase nephrotoxicity when used topically or systemically with cephalothin. 4. This product should not be used in combination with polymyxins, or applied topically or systemically in sequence, because it can increase nephrotoxicity and neuromuscular blocking effects, the latter of which can lead to skeletal muscle weakness, respiratory depression or respiratory paralysis (apnea). 5. This product should not be used in combination with other nephrotoxic or ototoxic drugs, or used sequentially, so as not to aggravate nephrotoxicity or ototoxicity. 6. This product should not be used in combination with amphotericin B, cephalothin sodium, nitrofurantoin sodium, sulfadiazine sodium and tetracycline hydrochloride (all of the above are injections), because incompatibility may occur. 7. This product can often achieve synergistic effects when combined with beta-lactams (cephalosporins or penicillins). 8. This product can be mixed with beta-lactams (cephalosporins or penicillins) to cause mutual inactivation. When used in combination, it must be dripped in separate bottles.

Keep tightly closed in a cool, dark place.

Calculate according to C22H43N5O12 2ml:0.2g

Zhejiang Hisun Pharmaceutical Co., Ltd.

• Founded in:

  1998-02-11

• Address:

  No. 46, Waisha Road, Jiaojiang District, Taizhou City, Zhejiang Province

• Tax NO.:

  91330000704676287N

• Registered Funds:

  1,207,873,716 yuan

• Website:

  Log in to view

• Email:

  Log in to view